Blog
RSS FeedPosted by Michael Wonder on 07 Jan 2020
Lokelma approved in China for the treatment of adult patients with hyperkalaemia
6 January 2020 - Patients in China will benefit from Lokelma’s rapid reduction of potassium in the blood and the ...
Posted by Michael Wonder on 05 Jan 2020
China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies
27 December 2019 - Second BeiGene discovered drug to receive regulatory approval, first in China. ...
Posted by Michael Wonder on 24 Dec 2019
AstraZeneca’s triple-combination therapy approved in China for patients with COPD
23 December 2019 - First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device in China. ...
Posted by Michael Wonder on 16 Dec 2019
China’s cancer patients hit by new law on experimental drug treatments not approved by government
11 December 2019 - The law came into effect on December 1 and forbids pharmaceutical firms giving patients drugs from unapproved ...
Posted by Michael Wonder on 09 Dec 2019
China to strengthen medicine price monitoring
9 December 2019 - China's National Healthcare Security Administration has issued a guideline to strengthen regular supervision on medicine prices. ...
Posted by Michael Wonder on 05 Dec 2019
How China’s new drug buying program is causing pain
6 December 2019 - China is overhauling its health-care system with the aim of providing broader access to quality drugs for ...
Posted by Michael Wonder on 02 Dec 2019
China updates drug reimbursement list, agrees price cuts
2 December 2019 - Drugs added include AbbVie's Humira and Roche's Perjeta. ...
Posted by Michael Wonder on 02 Dec 2019
National Medical Products Administration approves Chipscreen Bioscience's chidamide (Epidaza) for breast cancer indication
29 November 2019 - Shenzhen Chipscreen Biosciences announced that the company's lead innovative product Epidaza (chidamide), an oral subtype-selective histone ...
Posted by Michael Wonder on 28 Nov 2019
Sosei Heptares announces that the COPD treatment Ultibro Breezhaler has been included in the National Reimbursement Drug List in China
28 November 2019 - Sosei Group announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included ...
Posted by Michael Wonder on 28 Nov 2019
Tyvyt (sintilimab Injection), an innovative PD-1 inhibitor jointly developed by Innovent and Lilly, is included in the new catalogue of National Reimbursement Drug List
27 November 2019 - Innovent Biologics today jointly announced with Eli Lilly and Company that the innovative PD-1 inhibitor Tyvyt (sintilimab ...
Posted by Michael Wonder on 28 Nov 2019
Chi-Med’s Elunate (fruquintinib capsules) included in the National Reimbursement Drug List in China
28 November 2019 - Hutchison China MediTech today announces that Elunate (fruquintinib capsules), its national class 1 targeted anticancer drug for ...
Posted by Michael Wonder on 28 Nov 2019
Drug makers including Roche and Novartis slash medicine prices in China to get on reimbursement list
28 November 2019 - Drug makers including Roche and Novartis have agreed to cut the prices of some of their ...
Posted by Michael Wonder on 27 Nov 2019
Astellas announces the approval of Xtandi (enzalutamide) by the China National Medical Products Administration approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer
26 November 2019 - Astellas Pharma today announced that the China National Medical Products Administration approved a new drug application ...
Posted by Michael Wonder on 27 Nov 2019
Merck’s Keytruda (pembrolizumab) now approved in China for first-line treatment of metastatic squamous non-small cell lung cancer in combination with chemotherapy
26 November 2019 - Third approval for Keytruda in first-line NSCLC in China in less than one year. ...
Posted by Michael Wonder on 20 Nov 2019
China to promote centralised medicine procurement, use to ease patients' burden
20 November 2019 - China will improve its mechanism for centralized medicine procurement and use in a steady and orderly ...